Reckitt Benckiser Q1 2025: Emerging Markets surge +10.7%, Core Reckitt up +3.1%. 2025 outlook reaffirmed despite macro challenges. Key brands Durex & Dettol lead growth.
This article covers information on Reckitt Benckiser Group PLC.
LON:RKTReckitt Benckiser’s first quarter reads like a tale of two consumer landscapes. While developed markets grapple with what CEO Kris Licht diplomatically calls a “challenging macroeconomic outlook,” emerging markets are partying like it’s 1999. Let’s unpack what this means for investors.
Emerging markets delivered a barnstorming +10.7% LFL growth, contributing £1.04bn to the kitty. Three things stand out:
Pharmacy restocking cycles and nitrile condom rollouts can’t fully offset what looks suspiciously like consumers rationing their Nurofen. Bright spot? Germany and Italy going germ-crazy with Dettol.
Walgreens and CVS playing inventory Jenga with Mucinex stocks while Lysol tries to sanitise its way through supply chain growing pains. Club stores winning, drugstores… not so much.
Core Reckitt’s +3.1% growth hides fascinating category battles:
| Germ Protection | +7.5% | Dettol’s washing machine cleaners? Genius |
| Intimate Wellness | +16.6% | Hyaluronic acid condoms – because why not? |
That -7% LFL decline isn’t just about tough comps. Air Wick’s struggle against private label smells suspiciously like a business needing better perfume. Management’s “we’ll fix it in post-production” H2 recovery narrative? We’re keeping the smelling salts handy.
Reckitt’s holding firm on 2025 guidance like a climber with premium-grade carabiners:
This quarter proves Reckitt’s emerging markets engine can compensate for Western wobbles. With 40% of core revenue now from growth markets and nitrile condoms heading to a bedroom near you, the 2025 outlook looks achievable – if slightly dependent on China’s ongoing love affair with Western hygiene brands.
One to watch: how Essential Home’s potential sale plays out in a jittery market. For now, the Dettol-Durex double act deserves its standing ovation.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
48 viewsLikes
No ratings yet
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.